Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
9(53%)
Results Posted
100%(2 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
2
12%
Ph phase_2
6
35%
Ph phase_3
3
18%
Ph not_applicable
4
24%

Phase Distribution

2

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
2(13.3%)
Phase 2Efficacy & side effects
6(40.0%)
Phase 3Large-scale testing
3(20.0%)
N/ANon-phased studies
4(26.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

9

trials recruiting

Total Trials

17

all time

Status Distribution
Active(9)
Completed(2)
Terminated(2)
Other(4)

Detailed Status

Active, not recruiting7
unknown3
Completed2
Recruiting2
Suspended1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
9
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (13.3%)
Phase 26 (40.0%)
Phase 33 (20.0%)
N/A4 (26.7%)

Trials by Status

completed212%
recruiting212%
suspended16%
unknown318%
withdrawn16%
active_not_recruiting741%
terminated16%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT05630794Phase 1

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

Recruiting
NCT03955510Not Applicable

Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis

Active Not Recruiting
NCT03233711Phase 3

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Active Not Recruiting
NCT04751370Phase 2

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

Active Not Recruiting
NCT04929028Phase 2

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Active Not Recruiting
NCT01696981Not Applicable

Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)

Active Not Recruiting
NCT05610163Phase 2

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation

Active Not Recruiting
NCT06780787Phase 2

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Recruiting
NCT05209100

Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease

Active Not Recruiting
NCT05700331Not Applicable

Fecal Microbiota Transplantation for Patients With Chronic Widespread Pain

Suspended
NCT02928510

Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma

Terminated
NCT02049502Phase 2

FMT in Ulcerative Colitis-Associated Pouchitis

Completed
NCT02849821Not Applicable

The Altitude Inflammatory Bowel Disease Study

Unknown
NCT00893295Phase 3

Increasing Colorectal Cancer Screening in African Americans

Unknown
NCT00960427Phase 1

Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery

Withdrawn
NCT00867438Phase 2

Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy

Completed
NCT00139165Phase 3

Long-Term Treatment of Collagenous Colitis With Budesonide

Unknown

All 17 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
17